Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 126 are a BUY (75.45%), 39 are a HOLD (23.35%), 2 are a SELL (1.2%).
Analyst Judah Frommer works at CREDIT SUISSE with a stock forecast success ratio of 49.67% fulfilled within 138.52 days on average.
Judah Frommer’s has documented 310 price targets and ratings displayed on 29 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on JSPR, Jasper Therapeutics at 14-Aug-2023.
Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
160
$31.78 (24.79%)
160
1 months 9 days ago
8/24 (33.33%)
$31.58 (24.59%)
105
Buy
180
$51.78 (40.38%)
160
1 months 18 days ago
14/21 (66.67%)
$33.58 (22.93%)
468
Buy
160
$31.78 (24.79%)
135
2 months 15 days ago
2/3 (66.67%)
$20.17 (14.42%)
82
Buy
157
$28.78 (22.45%)
122
2 months 24 days ago
15/20 (75%)
$23.21 (17.35%)
302
Buy
171
$42.78 (33.36%)
160
3 months 19 days ago
18/23 (78.26%)
$34.28 (25.07%)
307
What Year was the first public recommendation made by Judah Frommer?